About Ribonexus

Ribonexus (previously Aglaia Therapeutics) is a biotechnology start-up developing promising new oncology therapies. The company aims to deliver best- and first- in class drugs that restore sensitivity to current targeted therapies in cancer patients that have become resistant to these treatments. Ribonexus has established a pipeline of small molecules, targeting the initiation of mRNA translation, which the company acquired and developed through Pierre Fabre.
Based in Villejuif, near Paris, France, Ribonexus was co-founded in 2021 by Advent France Biotechnology (AFB). To start its preclinical activities, the company raised €4M ($4.7M) in seed funding from AdBio partners, Credit Mutuel Innovation and Pierre Fabre.